Synonyms: AMG-899 | DEZ-001 | TA-8995 | TA8995
Compound class:
Synthetic organic
Comment: Obicetrapib is a clinical lead, orally bioavailable, small molecule, cholesterol ester transfer protein (CETP; P11597) inhibitor [1]. It was developed as a treament for dyslipidemia. Agents of the CETP class are proposed to increase HDL cholesterol, lower LDL cholesterol, and enhance reverse cholesterol transport, as a mechanism to reduce the risks of elevated cholesterol on atherosclerosis. Prior to the re-launching of trials involving obicetrapib by NewAmsterdam Pharma, no CETP inhibitor had demonstrated sufficient safety and/or efficacy in a clinical study to warrant continued development.
|
|
References |
1. Ford J, Lawson M, Fowler D, Maruyama N, Mito S, Tomiyasu K, Kinoshita S, Suzuki C, Kawaguchi A, Round P et al.. (2014)
Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol, 78 (3): 498-508. [PMID:24628035] |